C5a

Synonyms

Prepro-C5, CPAMD4, Complement C5, C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4, C5D, Complement Component 5, C5a, Anaphylatoxin C5a Analog, C5a Anaphylatoxin, C5b, ECLZB, C5,

Description

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

KO Status

F0

Drug Information

Launched drugs: 17
Drugs in clinical trials: 2
Latest Research Phase:Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Ravulizumab

ALXN-1210, ALXN-1810

Approved

Alexion Pharmaceuticals Inc

Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Glomerulonephritis, IGA, Coronavirus Disease 2019 (COVID-19), Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Respiratory Distress Syndrome, Adult, Lupus Nephritis, Neuromyelitis Optica, Pneumonia, Viral, Amyotrophic Lateral Sclerosis, Acute Lung Injury

Eculizumab

5G1-1, HAL-1, LEX-98, h-5G1.1

Approved

Alexion Pharmaceuticals

Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome, Delayed Graft Function, Neuromyelitis Optica, Asthma

Zilucoplan

RA-101495, RA-101495-SC

Phase 3 Clinical

Ra Pharma

Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Lupus Nephritis, Hemolytic-Uremic Syndrome

Avacincaptad pegol

ARC-187, ARC-1905

Phase 3 Clinical

Archemix

Geographic Atrophy, Stargardt Disease, Macular Degeneration

Vilobelimab

IFX-1, CaCP-29

Phase 3 Clinical

Beijing Mabworks Biotech Co Ltd, Inflarx

Shock, Septic, Granulomatosis with Polyangiitis, Pyoderma Gangrenosum, Microscopic Polyangiitis, Sepsis, Coronavirus Disease 2019 (COVID-19), Hidradenitis Suppurativa, Systemic Inflammatory Response Syndrome

BDB-001

BDB-001, BDB001, BDB 001

Phase 3 Clinical

Staidson(Beijing) Biopharmaceuticals Co Ltd

Coronavirus Disease 2019 (COVID-19), Neoplasms, Hidradenitis Suppurativa

Eculizumab biosimilar (Biocad)

BCD-148

Phase 3 Clinical

Biocad

Hemoglobinuria, Paroxysmal

Crovalimab

SKY-59, RG-6107, CH-7092230, RO-7092230, RO-7112689, RO-7112689/F01

Phase 3 Clinical

F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd

Hemoglobinuria, Paroxysmal

Eculizumab biosimilar (IBC GENERIUM)

Phase 3 Clinical

Ibc Generium

Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome

Eculizumab biosimilar (Amgen)

ABP-959

Phase 3 Clinical

Amgen Inc

Hemoglobinuria, Paroxysmal, Hemolytic-Uremic Syndrome

Pozelimab

REGN-3918

Phase 3 Clinical

Regeneron Pharmaceuticals Inc

Hemoglobinuria, Paroxysmal

Eculizumab biosimilar (CinnaGen)

Phase 3 Clinical

Cinnagen

Hemoglobinuria, Paroxysmal

Nomacopan

EV-576, rVA576, rEV-576

Phase 3 Clinical

Evolutec

Myasthenia Gravis, Hemoglobinuria, Paroxysmal, Arthritis, Rheumatoid, Sjogren's Syndrome, Autoimmune Diseases, Atypical Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Asthma, Keratoconjunctivitis, Inflammation, Guillain-Barre Syndrome

Eculizumab biosimilar (Samsung Bioepis)

SB-12

Phase 3 Clinical

Samsung Bioepis

Hemoglobinuria, Paroxysmal

Tesidolumab

NOV-4, LFG-316

Phase 2 Clinical

Novartis Pharma Ag, Morphosys Ag

Hemoglobinuria, Paroxysmal, Wet Macular Degeneration, Geographic Atrophy, Macular Degeneration

Olendalizumab

ALXN-1007

Phase 2 Clinical

Alexion Pharmaceuticals

Graft vs Host Disease, Antiphospholipid Syndrome, Rejection of organ transplantation, Inflammation

Cemdisiran

ALN-CC5

Phase 2 Clinical

Alnylam Pharmaceuticals Inc

Glomerulonephritis, IGA, Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome

ALXN-5500

ALXN-5500

Phase 1 Clinical

Alexion Pharmaceuticals Inc

Hemoglobinuria, Paroxysmal

ALXN-1720

ALXN-1720

Phase 1 Clinical

Alexion Pharmaceuticals

Pexelizumab

Discontinued

Stanford University

Reperfusion Injury, Myocardial Infarction